Rapid test for Alzheimer AZD05030 ;
Although disappointed AZD05030 of Astra Zeneca cancer researchers which surprisingly blocked damage Alzheimer plate. Learn about how quickly this compound moved into human trials.
The drug AZD05030 developed by Astra Zeneca been disappointing in the treatment of solid tumors, but appears to block the damage caused during the formation of beta-amyloid plaques characteristic of Alzheimer’s disease. The new study, funded by National Institutes of an innovative program to test drugs failed in diseases of Health (NIH), has led to the implementation of human trials to test the efficacy of AZD05030 in Alzheimer’s patients.
“With this treatment, the cells under the bombardment of amyloid plaques beta show restores synaptic connections and reduced inflammation, and memory of the animal, which was lost during the course of the disease returns “said Stephen M. Strittmatter, professor of Neurology Vincent Coates and lead author of the study.
In last five years, scientists have developed a more complete understanding of the complex chain of events that leads to Alzheimer’s disease. New drug blocks one of those molecular steps, FYN activating enzyme, which leads to loss of synaptic connections between brain cells. Several other steps in the disease process have the potential to be the target of new drugs, Strittmatter said.
“The speed with which this compound moved into human trials New Therapeutic Uses validates our model program and serves our mission to provide more treatments for more patients more quickly,” said Christopher P. Austin, MD, director National Health Center for the Advancement of Science translational (NCATS), which funded the work.
This article was originally published on alzheimersweekly, Read the original article here